ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
In first-line NSCLC (QUILT-2.023), a randomized study demonstrated a statistically significant and sustained increase in absolute lymphocyte count (ALC) from baseline with ANKTIVA plus CPI compared with CPI alone (p=0.0065), establishing ANKTIVA's contribution as a lymphocyte-stimulating agent In second- and later-line NSCLC (QUILT-3.055), a single-arm study demonstrated restoration or maintenance of ALC =1.0 × 10³ cells/µL in 77% of patients receiving ANKTIVA plus CPI (responders) Responders receiving ANKTIVA plus CPI experienced significantly longer overall survival compared with non-responders (median OS 16.2 vs 11.8 months; HR 0.52; p=0.0369), directly linking immune restoration to clinical benefit Patients achieving higher immune competence (ALC =1.2 ×10³ cells/µL) demonstrated additional survival benefit, with median OS of 21.1 months (HR 0.33; p=0.0009), independent of PD-L1 status, exceeding historical overall survival of 7-9 months with standard of care chemotherapy
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung CancerBusiness Wire
- NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security [Yahoo! Finance]Yahoo! Finance
- NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health SecurityBusiness Wire
- ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of "100 Most Influential People in Oncology in 2025" [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”Business Wire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 12/29/25 - Form 424B5
- IBRX's page on the SEC website